Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
12.00
+0.25 (2.13%)
Jun 21, 2024, 4:00 PM EDT - Market closed

Y-mAbs Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2016
Cash & Equivalents
78.64105.76181.56114.63207.14
Upgrade
Cash & Cash Equivalents
78.64105.76181.56114.63207.14
Upgrade
Cash Growth
-25.65%-41.75%58.39%-44.66%40.08%
Upgrade
Receivables
22.4512.537.7100
Upgrade
Inventory
5.076.75.5100
Upgrade
Other Current Assets
4.965.457.477.734.82
Upgrade
Total Current Assets
111.11130.45202.26122.36211.96
Upgrade
Property, Plant & Equipment
1.642.345.696.394.04
Upgrade
Goodwill and Intangibles
2.632.991.6600
Upgrade
Other Long-Term Assets
12.495.683.173.290.37
Upgrade
Total Long-Term Assets
16.7611.0110.529.684.41
Upgrade
Total Assets
127.87141.46212.78132.05216.37
Upgrade
Accounts Payable
6.0614.1813.559.378.52
Upgrade
Current Debt
0.90.871.781.970.52
Upgrade
Other Current Liabilities
13.1713.2412.548.24.55
Upgrade
Total Current Liabilities
20.1328.2827.8819.5413.59
Upgrade
Long-Term Debt
0.520.91.852.011.71
Upgrade
Other Long-Term Liabilities
6.243.052.954.662.16
Upgrade
Total Long-Term Liabilities
6.763.954.86.683.88
Upgrade
Total Liabilities
26.8832.2432.6826.2117.46
Upgrade
Total Debt
1.421.773.633.982.23
Upgrade
Debt Growth
-19.69%-51.38%-8.67%78.43%-
Upgrade
Retained Earnings
-457.47-436.04-340.48-285.2-165.86
Upgrade
Comprehensive Income
0.451.331.37-0.530.05
Upgrade
Shareholders' Equity
100.99109.22180.11105.84198.9
Upgrade
Net Cash / Debt
77.22104177.93110.66204.91
Upgrade
Net Cash / Debt Growth
-25.75%-41.55%60.80%-46.00%38.57%
Upgrade
Net Cash Per Share
1.772.384.122.765.82
Upgrade
Working Capital
90.98102.16174.39102.83198.37
Upgrade
Book Value Per Share
2.312.504.172.645.65
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).